The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

2015180 citationsJournal Articlebronze Open Access

Authors

Nicole R. Infarinato

Jin H. Park

Yaël P. Mossé · University of Pennsylvania

Abstract

The next-generation ALK/ROS1 inhibitor PF-06463922 exerts unparalleled activity in ALK-driven neuroblastoma models with primary crizotinib resistance. Our biochemical and in vivo data provide the preclinical rationale for fast-tracking the development of this agent in children with relapsed/refractory ALK-mutant neuroblastoma.

Topics & Keywords

Neuroblastoma Research and Treatments Cancer, Hypoxia, and Metabolism Cancer therapeutics and mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Discovery

Volume 6, Issue 1, pp. 96-107

DOI: 10.1158/2159-8290.cd-15-1056

Field-Weighted Citation Impact: 11.99